The FDA sent 30 warning letters to telehealth companies in March alone, and by the end of April, they proposed taking semaglutide, tirzepatide, and liraglutide off the 503B Bulk Drug Substances List altogether
Checklist for Traveling with GLP-1 Medications 1
Our approach promotes lasting results and balanced hormones, far beyond short-term scale victories
Recalls & Warnings June 25, 2019 Kratom Is Dangerous and Not Proven to Treat Addiction, FDA Warns Marketers On June 25, 2019, the FDA issued warning letter to two marketers and distributors of kratom products, listed below, for illegally selling unapproved, misbranded kratom-containing drug products with unproven claims about their ability to treat or cure opioid addiction and withdrawal symptoms
The product is formulated to support skin health from the inside out
This enzyme reduces GSSG (oxidized glutathione) to two molecules of glutathione (GSH) using NADPH and a proton (H + ), releasing NADP +